Japanese Yen Nears Seven-Month High as Oil Approaches $100 
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Japan Producer Inflation Eases to 7.6% in August 
Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites 
Norway Core Inflation Rises to 3% in August 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Asian Stocks Slide as Oil Surge Fuels Rate Hike Fears 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
Kioxia Rules Out SK Hynix Manufacturing Partnership 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
Fitch Eyes Japan Budget for Fiscal Discipline 
Zara Owner Inditex Sales Rise 9% in August 
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure 
White House Weighs Refined Copper Tariffs as Cost Concerns Grow 
Add as a preferred source on Google
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
